ORXOF News 19.0800 Orexo (ORXOF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Orexo (ORXOF) 19.0800 $ORXOF

Orexo AB announces conversion of convertible bonds into shares
M2 - Mon Aug 26, 6:17AM CDT
Speciality pharmaceutical company Orexo AB (STO:ORX.ST) announced today the conversion of a convertible bond issue, subscribed by Novo A/S, into shares on 23 August 2013.

U.S. FDA Approves Zubsolv® for the Maintenance Treatment of Opioid Dependence
PR Newswire - Fri Jul 05, 7:00AM CDT
Orexo U.S., Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII). Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is a once-daily, sublingual tablet with higher bioavailability, a fast dissolve time, smaller tablet size and a new menthol flavor.

Orexo's Zubsolv receives US FDA approval
M2 - Thu Jul 04, 10:55AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the receipt of approval from the US Food and Drug Administration (FDA) for Zubsolv (buprenorphine/naloxone) sublingual tablet CIII.

Acute Pain - Pipeline Review, H1 2013
M2 - Fri Apr 05, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gdw5kx/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2013" report to their offering. 'Acute Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Acute Pain. - Identi

2 Bio Stock Reports: (NASDAQ: GALE), (NASDAQ: ARRY)
ACCESSWIRE-TNW - Tue Mar 26, 2:20AM CDT
New York (March 26th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced last week that it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.

2 BIO Stocks in the News: (NASDAQ: GALE), (NYSE: NAVB)
ACCESSWIRE-TNW - Tue Mar 19, 12:22AM CDT
New York (March 19th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.

Orexo sells Abstral in the US to Galena Biopharma for USD10m upfront
M2 - Mon Mar 18, 1:40PM CDT
Speciality pharma company Orexo AB (STO:ORX.ST) announced today the sale of Abstral (fentanyl) sublingual tablets in the US to Galena Biopharma Inc (Nasdaq:GALE), a biopharmaceutical company.

Orexo AB announces divestiture of Abstral in the US for USD10m upfront
M2 - Mon Mar 18, 6:50AM CDT
Specialist pharma company Orexo AB (Stockholm:ORX.ST) revealed on Monday the sale of its FDA approved Abstral (fentanyl) Sublingual Tablets in the US to Galena Biopharma, Inc (NasdaqCM:GALE) for USD10m upfront .

Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi

Orexo names Nikolaj Sorensen as new CEO and Martin Nicklasson as Executive Chairman
M2 - Tue Feb 05, 5:08AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) today announced that Nikolaj Sorensen, currently chief commercial officer of Orexo, will be promoted as CEO of the company.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 41

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 72

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 111

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Fluor Corporation Investors Alert: Join the Class Action Now

Updated Category News Views 153

Fluor Corporation Class Action Overview The Portnoy Law Firm has issued an important announcement regarding Fluor Corporation's recent class action lawsuit. Investors who purchased securities of Fluor during a specified period are encouraged to participate. Details of the Class Action This class action is targeting investors who acquired Fluor Corporation shares from...

Continue Reading
Maravai LifeSciences Investors: Are You Affected by Recent Issues?

Updated Category News Views 141

Maravai LifeSciences Holdings, Inc. Overview Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has quickly become a pivotal player in the biopharmaceutical sector. Their innovative approach and dedication to improving scientific methods have attracted attention from investors and stakeholders alike. However, recent events have thrown some uncertainty into the landscape...

Continue Reading
Gesa Credit Union Acquires Willamette Valley Bank

Updated Category News Views 73

Community Banking Shake-Up in the Pacific Northwest Ah, mergers and acquisitions—they’re like spices in the economic salsa. Today's special? Gesa Credit Union, one of Washington’s powerhouses, deciding to acquire Willamette Valley Bank. Nothing gets the business blood pumping like a good ol' fashioned acquisition. The Financial Backdrop This deal isn't some casual...

Continue Reading
Market Uncertainty Eases as Economic Data Floods In

Updated Category News Views 181

Market Uncertainty Eases as Economic Data Floods In The US government shutdown has come to an end. However, as soon as the funding bill was signed, the markets shifted their focus toward the substantial economic data that has been delayed for over six weeks. This hiatus lasted for forty-three days without any federal reporting, resulting in a significant gap in available...

Continue Reading
AIM Congress 2026: Shaping Future Investment Pathways

Updated Category News Views 510

Exciting News About AIM Congress 2026 The Organizing Committee of AIM Congress, the foremost investment platform globally, has announced the launch of its 15th edition, centered around the compelling theme: Reshaping Global Prosperity: Unlocking New Investment Pathways Towards a Sustainable and Inclusive Future. This prestigious event is set to take place in April 2026 at...

Continue Reading